Exciting times await the field of protein engineering, where new techniques such as deep sequencing, single cell screening and gene editing are moving from theory to practice, bringing scientists one step closer to better understanding the sequence and structure-function of the molecules, and closing the gap from bench to clinic.

The 4th Annual Engineering Antibodies conference at PEGS Europe explores the emerging modalities, the latest technologies and the new approaches used by protein scientists to discover, design and optimize their molecules against existing and challenging targets in the various therapeutic areas.  

Coverage will include, but is not limited to:


  • Antibodies Against Difficult Targets (GPCR, Ion Channels)
    • Challenges in targeting and specificity
  • Novel Modalities for Oncology and Beyond - Overcoming Challenges in Cell Lines, Expression, Specificity, Toxicity and Stability
    • Bispecifics/multispecifics, rna-based therapeutics, chemibodies, nanoparticles, radiotherapies, fusion proteins, antibody fragments and mixtures
    • CAR-T
    • Gene Therapies
    • Nanoparticles
    • Radio-conjugated therapeutics
    • Antibody fragments and mixtures
    • Fusion proteins
    • Immunomodulators
    • Biologics with Conditional Activation 
  • Minimising the Gap from in vitro to Clinic
    • Animal models beyond mice - chickens, llama
    • Biomarkers for patient selection
  • Deep Sequencing and Deep Learning for Antibody Engineering and Optimisation
  • Machine Learning/Computational Approaches to Antibody Design and Structure-Guided Engineering
  • Pharmacometrics/Quantitative Pharmacology to Determine Drug Distribution
  • Single Cell Screening and Cloning Platforms and Applications
  • CRISPR/Gene Editing Applications in Research, Diagnostics, Translational Sciences and Clinic 

* The program is subject to change without notice, due to unforeseen reason.